EDESA BIOTECH, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
EDESA BIOTECH, INC. (EDSA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$13.34 million for the 12-month period ending 2021-09-30, per its 10-K filed 2021-12-28.
Discontinued › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2021-12-28
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-09-30 was -$3.69M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-06-30 was -$4.76M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2021-03-31 was -$2.26M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2020-12-31 was -$2.64M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$13.34M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2020 was -$6.36M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2018 was -$4.31M.
- EDESA BIOTECH, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2017 was -$4.54M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 1 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|---|
| 2021-09-30 | -$3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | -$8.45M derived: sum of 2 quarters · filed 2021-12-28 | -$10.70M derived: sum of 3 quarters · filed 2021-12-28 | -$13.34M 10-K · filed 2021-12-28 | |
| 2021-06-30 | -$4.76M 10-Q · filed 2021-08-13 | -$7.02M derived: sum of 2 quarters · filed 2021-08-13 | -$9.66M 10-Q · filed 2021-08-13 | -$11.67M derived: sum of 4 quarters · filed 2021-12-28 | |
| 2021-03-31 | -$2.26M 10-Q · filed 2021-05-14 | -$4.90M 10-Q · filed 2021-05-14 | -$6.91M derived: sum of 3 quarters · filed 2021-12-28 | -$8.68M derived: sum of 4 quarters · filed 2021-12-28 | |
| 2020-12-31 | -$2.64M 10-Q · filed 2021-02-16 | -$4.65M derived: sum of 2 quarters · filed 2021-12-28 | -$6.42M derived: sum of 3 quarters · filed 2021-12-28 | -$7.91M derived: sum of 4 quarters · filed 2021-12-28 | |
| 2020-09-30 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | -$3.78M derived: sum of 2 quarters · filed 2021-12-28 | -$5.27M derived: sum of 3 quarters · filed 2021-12-28 | -$6.36M 10-K · filed 2021-12-28 | |
| 2020-06-30 | -$1.77M 10-Q · filed 2021-08-13 | -$3.26M derived: sum of 2 quarters · filed 2021-08-13 | -$4.35M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$1.49M 10-Q · filed 2021-05-14 | -$2.58M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$1.09M 10-Q · filed 2021-02-16 | ||||
| 2019-09-30 | -$2.78M 10-K · filed 2020-12-07 | ||||
| 2019-06-30 | -$1.29M 10-Q · filed 2020-08-12 | -$1.82M derived: sum of 2 quarters · filed 2020-08-12 | -$2.19M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | -$528.83K 10-Q · filed 2020-05-15 | -$893.68K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$364.85K 10-Q · filed 2020-02-13 | ||||
| 2018-09-30 | -$4.31M 10-K · filed 2018-11-30 | ||||
| 2017-09-30 | -$4.54M 10-K · filed 2018-11-30 | ||||
| 2016-09-30 | -$4.00M 10-K · filed 2017-12-01 | ||||
| 2015-09-30 | -$3.26M 10-K · filed 2017-12-01 | ||||
| 2014-09-30 | -$334.84K 10-K · filed 2016-12-14 | ||||
| 2014-08-31 | -$4.18M 10-K · filed 2016-12-14 | ||||
| 2013-08-31 | -$2.08M 10-K · filed 2015-12-14 | ||||
| 2012-08-31 | -$3.77M 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |